Vielbeachtet, vielzitiert
advanceCOR ist ein forschungsstarkes Unternehmen. Unsere Wissenschaftler publizieren ihre Ergebnisse regelmäßig in renommierten Fachjournalen.
2022
Contursi A, Ballerini P, Alberti S, Münch G, Patrignani P. The Novel Antiplatelet Agent Revacept in Cardiovascular Medicine: The Promise of Efficacy Without Bleeding. J Clin Cardiol. 2022;3(1):12-20. – hier als PDF lesen
Zhongmin Li, Goetz Muench, Clara Wenhart, Silvia Goebel & Andreas Reimann. Definition of a sectioning plane and place for a section containing hoped-for regions using a spare counterpart specimen. Nature/Scientifc Reports 12, Article number: 13342 (2022) https://doi.org/10.1038/s41598-022-17380-z – hier als PDF lesen
Uphaus T; Richards T; Weimar C; Neugebauer H; Poli S; Weissenborn K; Imray C; Michalski D; Rashid H; Loftus I; Rummey C; Ritter M; Hauser T-K; Münch G; Gröschel K; Poppert H. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial, Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.037006 – hier als PDF lesen
2021
Mayer K, Hein-Rothweiler R, Schüpke S, et al. for the ISAR-Plaster investigators | Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease TheRandomized, Double-blind, Placebo-Controlled ISAR-PLASTERPhase 2 Trial – hier als PDF lesen
Mayer K, Hein-Rothweiler R, Schüpke S, et al. | Supplemental Online Content – Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein vi, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial. JAMA Cardiol. Published online March 31, 2021. doi:10.1001/jamacardio.2021.0475 hier als PDF lesen
Zhongmin Li, Martin Ungerer, Julia Faßbender, Clara Wenhart, Hans-Peter Holthoff, Goetz Muench. Tissue block staining and domestic adhesive tape yield qualified integral sections of adult mouse orbits and eyeballs. PLOS ONE Artikel online lesen oder hier als PDF lesen
Clara Wenhart, Hans‑Peter Holthof, Andreas Reimann, Li Zhongmin, Julia Faßbender, Martin Ungerer – A fructosylated peptide derived from a collagen II T cell epitope for long‑term treatment of arthritis (FIA‑CIA) in mice. Nature/Scientifc Reports 2021 11:17345 Artikel online lesen oder hier als PDF lesen
2020
Gröschel K, Uphaus T, Loftus I., Poppert H, Diener HC, Zobel J, Münch G. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial. Volume 04, Number 04 of TH Open – Artikel online lesen oder Artikel hier als PDF lesen
Hans-Peter Holthoff, Kerstin Uhland, Gabor Laszlo Kovacs, Andreas Reimann, Kristin Adler, Clara Wenhart and Martin Ungerer. Thyroid-stimulating hormone receptor (TSHR) fusion proteins in Graves’ disease. Journal of Endocrinology (2020) Artikel online lesen oder Artikel hier als PDF lesen
Sara Alberti, Qianqian Zhang, Ilaria D’Agostino, Annalisa Bruno, StefaniaTacconelli, Annalisa Contursi, Simone Guarnieri , Melania Dovizio, Lorenza Falcone , Patrizia Ballerini, Götz Münch , YingYu & Paola Patrignani. The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia. Nature Research Scientifc Reports Artikel online lesen oder Artikel hier als PDF lesen
2019
Zeibig S, Büttcher M, Goebel S, Pauli J, Hunger A, Ungerer M, Gawaz M Münch G. The Scavenger Receptor CD68 Regulates Platelet Mediated Oxidized Low-Density Lipoprotein (oxLDL) Deposition in Atherosclerotic Vessels at an Early Stage of Atherosclerosis in LDLR-/-/ApoBec-/- Mice. Cell Physiol Biochem 2019;52;681-695 – Artikel online lesen oder hier als PDF lesen
Faßbender J, Holthoff HP, Li Z, Ungerer M. Therapeutic Effects of Short Cyclic and Combined Epitope Peptides in a Long-Term Model of Graves’ Disease and Orbitopathy. THYROID Volume 29, Number 2, 2019 – Artikel hier als PDF lesen
2018
Boivin-Jahns V, Uhland K, Holthoff H-P,Beyersdorf N, Kocoski V, Kerkau T, Münch G, Lohse M. Ungerer M, Jahns R. Cyclopeptide COR-1 to treat beta1-adrenergicreceptor antibody-induced heart failure. PLoS ONE13(8): publ Aug 20, 2018 – Artikel hier als PDF lesen
2017
Holthoff HP, Li Z, Faßbender J, Reimann Adler K, Münch G, Ungerer M, Cyclic Peptides for effective treatment in a long term model of Graves Disease and Orbitopathie in female mice , Endocrinology 158:1-16, 2017 – Artikel hier als PDF lesen
Mojica Muñoz AK, Jamasbi J, Uhland K, Degen H, Münch G, Ungerer M, Megens R, Weber C, Lorenz R, Brandl R, Siess W. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation. Thromb Haemost. 2017; 117(8):1651-1659 – Artikel online lesen
Degen H, Borst O, Ziegler M, Mojica Munoz AK, Jamasbi J, Walker B, Göbel S, Fassbender J, Adler K, Brandl R, Münch G, Lorenz R, Siess W, Gawaz M, Ungerer M. ADPase CD 39 fused to glycoprotein VI boosts local anti-thrombotic effects at vascular lesions. J Am Heart Ass 2017, 6:e005991; as of July 27, 2017 – Artikel online lesen oder hier als PDF lesen
2016
Ungerer M, Faßbender J, Li Z, Münch G, Holthoff HP. Review of Mouse Models of Graves’ Disease and Orbitopathy—Novel Treatment by Induction of Tolerance. Clinic Rev Allerg Immunol /2016-016-8562-7 – Artikel hier als PDF lesen
Baumgartner C, Brandl J, Münch G, , Ungerer M. Rabbit models to study atherosclerosis and its complications e Transgenic vascular protein expression in vivo Progress in Biophysics and Molecular Biology 121 (2016) 131e141 – Artikel online lesen
2015
J Am Coll Cardiol | Kommentiert in: Kleiman NS; Kolandaivelu K. Expanding the Roster : Developing New Inhibitors of Intravascular Thrombosis. 2015; 65 (22): 2416 – 2419 – Artikel online lesen
Jamasbi J, Megens RTA, Bianchini M, Münch G, Ungerer M, Faussner A, Sherman S, Walker A, Goyal P, Jung S, Brandl R, Weber C, Lorenz R, Elia N, Farndale J, Siess W. Differential inhibition of human atherosclerotic plaque- induced platelet activation by dimeric GPVI-Fc and anti-GPVI antibodies: functional and imaging studies. J Am Coll Cardiol 2015; 65 (22): 2404-2415 – Artikel online lesen
Holthoff HP, Goebel S, Li Z, Faßbender J,Reimann A, Zeibig S, Lohse M, Münch G, Ungerer M. Prolonged TSH Receptor A Subunit Immunization of Female Mice Leads to a Long-Term Model of Graves’Disease, Tachycardia, and Cardiac Hypertrophy. Endocrinology, April 2015, 156(4):1577–1589 – Artikel hier als PDF lesen
2013
Ungerer M, Münch G. Novel antiplatelet drugs in clinical development. Thromb Haemost 2013; 110 – Artikel online lesen
Dovizio M, Maier TH, Alberti S, Di Francesco L, Marcantoni E, Münch G, John C, Suess B, Sgambato A, Steinhilber D, Patrignani P. Pharmacological Inhibition of Platelet-Tumor Cell Cross-Talk Prevents Platelet-Induced Overexpression of Cyclooxygenase-2 in HT29 Human Colon Carcinoma Cells. Mol Pharmacol 84:25–40, July 2013 – Artikel hier als PDF lesen
Ungerer M, Li ZM, Baumgartner C, Göbel S, Vogelmann J, Holthoff HP, Bültmann A, Gawaz M, Münch G. The GPVI – Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLOS ONE 2013; 8(8):e71193 – Artikel online lesen
Göbel S, Li ZM, Vogelmann J, Holthoff HP, Degen H, Hermann DM, Gawaz M, Ungerer M, Münch G. The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. PLOS ONE 2013, 8(7):e66960 – Artikel online lesen
2010 - 2012
Baumer Y, Leder C, Ziegler M, Schönberger T, Ochmann C, Perk A, Degen H, Schmid-Horch B, Elvers M, Münch G, Ungerer M, Schlosshauer B, Gawaz M. The recombinant bifunctional protein aCD133–GPVI promotes repair of the infarcted myocardium in mice. J Thromb Haemost 2012; 10: 1152–64 – Artikel hier als PDF lesen
Bültmann A, Li Z, Wagner S, Peluso M, Schönberger T, Weis C, Konrad I, Stellos K, Massberg S, Nieswandt B, Gawaz M, Ungerer M, Münch G. Impact of glycoprotein VI and platelet adhesion on atherosclerosis–a possible role of fibronectin. J Mol Cell Cardiol 2010; 49(3):532-42 – Artikel online lesen
Zeibig S, Li Z, Wagner S, Holthoff HP, Ungerer M, Bültmann A, Uhland K, Vogelmann J, Simmet T, Gawaz M, Münch G. Effect of the oxLDL binding protein Fc-CD68 on plaque extension and vulnerability in atherosclerosis. Circulation Research 2011; 108:695-703 – Artikel online lesen
Ungerer M, Rosport K, Bültmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, Münch G. The novel anti-platelet drug Revacept (dimeric GPVI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general haemostasis in humans. Circulation 2011; 123: 1891-1899. – Artikel online lesen
Bültmann A, Li Z, Wagner S, Gawaz M, Ungerer M, Langer H, May A, Münch G. Loss of protease activity of ADAM15 abolishes protective effects on plaque progression in atherosclerosis. Int J Cardiol 152_2011 pp. 382-385 – Artikel hier als PDF lesen
Holthoff HP, Zeibig S, Jahns-Boivin V, Bauer J, Lohse M, Kääb S, Clauss S, Jahns R, Schlipp A, Münch G, Ungerer M. Detection of Anti–β1-AR Autoantibodies in Heart Failure by a Cell-Based Competition ELISA. Circulation Research. 2012;111:675–684 – Artikel online lesen oder hier als PDF lesen